CVS Health (CVS) Maintains Overweight Rating at Cantor Amid Membership Data Discrepancies

Cantor Fitzgerald analysts reaffirmed their price target of $71 and Overweight rating on CVS Health Corporation (NYSE:CVS) on June 4. The analysts pointed out disparities in the enrollment data, emphasizing in particular that when recent contract wins are taken into account, CVS Health’s membership numbers seem understated.

CVS Health (CVS) Maintains Buy Rating at Cantor Amid Membership Data Discrepancies

Pixabay/Public Domain

The analysts noticed a minor decline in enrollment across six payors, including Medicaid, in the enrollment files, which now include around half of the April data. According to the report, despite CVS Health’s consensus forecasts increase, the numbers do not include the 77,000 lives added as a result of a Pennsylvania contract that went into effect on January 1, 2025. This change raises the possibility that the consensus estimates for CVS Health Corporation (NYSE:CVS) are conservative. Furthermore, according to Cantor Fitzgerald, no new contracts are anticipated to begin in the second quarter of 2025.

CVS Health Corporation (NYSE:CVS) is an American healthcare company that maintains a large network of retail pharmacies and clinics nationwide. Its main brands include CVS Pharmacy, a retail drugstore chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider.

While we acknowledge the potential of CVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CVS and that has 100x upside potential, check out our report about the cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.